X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs FRESENIUS KABI ONCO. - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA FRESENIUS KABI ONCO. SANOFI INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 33.5 22.1 151.3% View Chart
P/BV x 6.4 3.1 204.8% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
FRESENIUS KABI ONCO.
Mar-13
SANOFI INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs4,560176 2,590.9%   
Low Rs4,40079 5,605.1%   
Sales per share (Unadj.) Rs1,028.537.7 2,729.1%  
Earnings per share (Unadj.) Rs129.05.1 2,532.0%  
Cash flow per share (Unadj.) Rs186.06.7 2,766.2%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.642.5 1,771.4%  
Shares outstanding (eoy) m23.03158.23 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.4 129.0%   
Avg P/E ratio x34.725.0 139.0%  
P/CF ratio (eoy) x24.118.9 127.3%  
Price / Book Value ratio x5.93.0 198.7%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,17420,135 512.4%   
No. of employees `0003.61.2 314.5%   
Total wages/salary Rs m3,592703 510.8%   
Avg. sales/employee Rs Th6,537.75,176.2 126.3%   
Avg. wages/employee Rs Th991.4610.4 162.4%   
Avg. net profit/employee Rs Th819.8699.6 117.2%   
INCOME DATA
Net Sales Rs m23,6865,963 397.2%  
Other income Rs m70818 3,933.3%   
Total revenues Rs m24,3945,981 407.9%   
Gross profit Rs m5,2811,430 369.3%  
Depreciation Rs m1,313258 509.1%   
Interest Rs m15-26 -57.7%   
Profit before tax Rs m4,6611,216 383.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,691342 494.2%   
Profit after tax Rs m2,970806 368.5%  
Gross profit margin %22.324.0 93.0%  
Effective tax rate %36.328.1 128.9%   
Net profit margin %12.513.5 92.8%  
BALANCE SHEET DATA
Current assets Rs m15,6735,102 307.2%   
Current liabilities Rs m6,6782,385 280.0%   
Net working cap to sales %38.045.6 83.4%  
Current ratio x2.32.1 109.7%  
Inventory Days Days76150 50.7%  
Debtors Days Days22113 19.7%  
Net fixed assets Rs m8,0985,148 157.3%   
Share capital Rs m230158 145.6%   
"Free" reserves Rs m17,0886,556 260.7%   
Net worth Rs m17,3566,732 257.8%   
Long term debt Rs m0952 0.0%   
Total assets Rs m25,40010,388 244.5%  
Interest coverage x311.7-45.8 -681.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.6 162.5%   
Return on assets %11.87.5 156.5%  
Return on equity %17.112.0 142.9%  
Return on capital %26.914.6 184.5%  
Exports to sales %24.574.5 32.9%   
Imports to sales %28.024.8 112.9%   
Exports (fob) Rs m5,8014,441 130.6%   
Imports (cif) Rs m6,6271,477 448.6%   
Fx inflow Rs m7,1455,298 134.9%   
Fx outflow Rs m6,8461,772 386.3%   
Net fx Rs m2993,525 8.5%   
CASH FLOW
From Operations Rs m3,2261,274 253.2%  
From Investments Rs m-1,555-1,204 129.1%  
From Financial Activity Rs m-1,818-196 927.1%  
Net Cashflow Rs m-147-126 116.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 81.0 74.6%  
Indian inst/Mut Fund % 14.4 0.3 4,800.0%  
FIIs % 14.6 9.6 152.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   15,184 42,599 35.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 02:15 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. REDDYS LAB COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS